Oxford Genetics receives £1m investment
The injection of capital follows an impressive year of growth for the company.
A leading biotechnology company with expertise in DNA design is set to benefit from a £1 millon investment to support its growth strategy and assist in the delivery of new services for cancer fighting gene therapy technologies.
Oxford Genetics has secured the financing from Mercia Technologies, which is making the investment as part of its focus on supporting the creation, funding and scaling of innovative technology businesses with high growth potential.
The injection of capital follows an impressive year of growth for Oxford Genetics, which recently announced its relocation to new, state-of-the-art facilities in Oxford Science Park. The move enables its team to access dedicated cell development suites and new technology capable of automating certain processes, allowing the DNA expert to scale its services in line with increasing customer demand.
Commenting on the investment, Dr Ryan Cawood, CEO at Oxford Genetics, said: “We are pleased to receive this investment from Mercia, which follows a period of sustained and exciting growth for Oxford Genetics. Our biotech business has grown significantly in the last year, and is now looking to reinforce its position as the world leader in DNA design, protein expression, and virus and cell line engineering.
“With Mercia’s capital and support, as well as the move to our new facilities, we are confident that we can continue to scale the business into a global provider of synthetic biology solutions.”
Oxford Genetics first received investment from Mercia in July 2015, after being identified as the next ‘Emerging Star’ from Mercia’s third party funds. Mercia Technologies now holds a 46% share in the company and this latest round of funding will enable Oxford Genetics to continue licensing its technologies within the rapidly expanding markets of cell and gene therapy.Dr Mark Payton, CEO of Mercia Technologies PLC, said: “Synthetic biology is a key sub-sector for Mercia and the Board was pleased to be able to make a further investment in Oxford Genetics as it moves to a “pivotal stage” of its DNA design development.
“We are confident that with our support Oxford Genetics will continue to scale becoming what we believe will be a global provider of synthetic biology solutions, in what is a very attractive and growing market.”Related News
-
News Patients vs Pharma – who will the Inflation Reduction Act affect the most?
The Inflation Reduction Act brought in by the Biden administration in 2022 aims to give better and more equitable access to healthcare in the USA. However, pharma companies are now concerned about the other potential costs of such legislation. -
News CPHI Podcast Series: What does the changing US Pharma market mean for industry and patients alike?
In this week's episode of the CPHI Podcast Series Lucy Chard, Digital Editor for CPHI Online is joined by James Manser to discuss the political and market changes in the US pharma field. -
News CPHI Barcelona Annual Report illuminates industry trends for 2024
The CPHI Annual Survey comes into it’s 7th year to report on the predicted trends for 2024. Over 250 pharma executives were asked 35 questions, with their answers informing the industry landscape for the next year, spanning all major pharma marke... -
News Which 10 drugs are open to price negotiation with Medicare in the USA?
The Centres for Medicare & Medicaid Services, under the Biden administration in the USA, has released a list of the 10 drugs that will be open to price negotiations as part of the new legislation under the Inflation Reduction Act (IRA). -
News EU Medical Devices Regulation causes unintended disappearances of medical devices for children, doctors state
Doctor groups and associations have appealed to the EU to correct the EU Medical Devices Regulation law that may cause unintended shortages of essential drug and medical devices for children and rare disease patients. -
News 10 Major Drug Approvals So Far in 2023
Last year, 37 novel drugs were approved by the FDA, this was a high number for such a category, and covered many fields including oncology, demonstrating how promising further research is, and how it is only continuing to build. To date, there are alre... -
News Detecting Alzheimer's disease with a simple lateral flow test
A novel rapid diagnostic test for early-stage Alzheimer's disease has been developed using a biomarker binder from Aptamer Group along with technology from Neuro-Bio, the neurodegenerative disease experts. -
News CPHI Podcast Series: outsourcing and manufacturing trends
Listen to the CPHI Podcast Series this June to hear Gil Roth of the PBOA speak with Digital Editor Lucy Chard about the biggest trends and topics to watch in pharma outsourcing and manufacturing at the minute.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance